BRIEF published on 03/03/2026 at 22:35, 3 months 11 days ago DBV Technologies: Update on voting rights and shares Euronext Paris Share Capital Voting Rights Financial Regulations DBV Technologies
BRIEF published on 03/03/2026 at 22:35, 3 months 11 days ago DBV Technologies: February 2026 Voting Rights and Shares Update Voting Rights Shares DBV Technologies NYSE Euronext Paris February 2026
PRESS RELEASE published on 03/03/2026 at 22:30, 3 months 11 days ago Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 Important update on total voting rights and shares as of February 28, 2026 for NYSE Euronext Paris. Total gross voting rights: 278,352,082 Shares Total Voting Rights Regulations NYSE Euronext Paris February 28 2026
BRIEF published on 03/02/2026 at 15:53, 3 months 12 days ago JP Morgan's investment in DBV Technologies reaches new thresholds Crossing Thresholds Equity Swaps Shares And Voting Rights DBV Technologies JP Morgan
BRIEF published on 02/28/2026 at 20:30, 3 months 14 days ago DBV Technologies reveals promising new results for VIASKIN Peanut Clinical Study Immunotherapy DBV Technologies Food Allergies Viaskin Peanut
BRIEF published on 02/28/2026 at 20:30, 3 months 14 days ago DBV Technologies Unveils Promising Phase 3 VITESSE Study Results at AAAAI 2026 DBV Technologies Phase 3 Results Viaskin Peanut Patch Peanut Allergy Treatment VITESSE Study
PRESS RELEASE published on 02/28/2026 at 20:25, 3 months 14 days ago DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting DBV Technologies presents successful Phase 3 VITESSE study data at AAAAI Annual Meeting, highlighting VIASKIN Peanut Patch efficacy in treating peanut-allergic children DBV Technologies Food Allergies Viaskin Peanut Patch Phase 3 VITESSE Study AAAAI Annual Meeting
BRIEF published on 02/09/2026 at 22:35, 4 months 5 days ago DBV Technologies to Join Guggenheim Biotech Summit Biopharmaceutical DBV Technologies Food Allergies VIASKIN® Patch Guggenheim Securities Summit
BRIEF published on 02/09/2026 at 22:35, 4 months 5 days ago DBV Technologies at the Emerging Outlook: Biotech Summit conference Immunotherapy DBV Technologies Viaskin Food Allergies Biotech Summit
PRESS RELEASE published on 02/09/2026 at 22:30, 4 months 5 days ago DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit DBV Technologies to participate in Guggenheim Securities Biotech Summit with CEO Daniel Tassé presenting at the fireside chat on February 12, 2026. Company focusing on food allergy treatment Guggenheim Securities DBV Technologies Food Allergies VIASKIN Patch Biotech Summit
Published on 06/13/2026 at 04:50, 1 day 22 hours ago BTU Additional Details Regarding Recent Acquisition
Published on 06/13/2026 at 02:00, 2 days ago Battery X Metals Appoints Automotive Industry Professional from Canadian Subsidiary of One of the World's Leading Premium Automobile Manufacturers, Headquartered in Munich, Germany, to its Advisory Board to Advance Commercialization of Its Patent-Pending
Published on 06/12/2026 at 23:15, 2 days 3 hours ago BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Published on 06/12/2026 at 22:30, 2 days 4 hours ago Fox River Provides Reminder To Vote And Updated Dissent Rights
Published on 06/12/2026 at 15:14, 2 days 11 hours ago Reeflex Solutions Inc. Reports Voting Results From Annual and Special Meeting of Shareholders
Published on 06/14/2026 at 14:50, 12 hours 8 minutes ago Zug voters say yes to Metalli development plan
Published on 06/14/2026 at 13:30, 13 hours 28 minutes ago Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
Published on 06/14/2026 at 10:42, 16 hours 16 minutes ago LightOn Demonstrates the Flexibility of Its OCR Model by Adapting It to Arabic Through Targeted Training.
Published on 06/13/2026 at 08:18, 1 day 18 hours ago EQS-Adhoc: AT&S Austria Technologie & Systemtechnik AG: AT&S expands AI substrate capacity in Kulim and increases outlook for 2026/27
Published on 06/13/2026 at 01:05, 2 days 1 hour ago OpenText to Create 400 Jobs with €105 Million Investment in Cork and Galway to Expand Agentic AI and Sovereign Cloud in Europe
Published on 06/12/2026 at 09:00, 2 days 17 hours ago Pricing of Green Senior Secured Notes due 2031 by Neoen FINCO PLC
Published on 06/11/2026 at 17:45, 3 days 9 hours ago BAIKOWSKI: Annual General Meeting of June 11, 2026 - Dividend of €0.30 per share, to be paid out on June 30, 2026
